Investigating how bariatric surgery affects cancer risk, supporting novel studies, exploring unknown mechanisms with the aim of finding proof of concept.
Funder: National Institutes of Health
Due Dates: February 16, 2027 (New) | March 16, 2027 (Resubmission/Revision) | June 16, 2027 (New) | July 16, 2027 (Resubmission/Revision) | October 16, 2027 (New) | November 16, 2027 (Resubmission/Revision) | January 7, 2028 (Closing date)
Funding Amounts: Up to $275,000 in direct costs over two years, with no more than $200,000 in one year.
Summary: NCI supports exploratory, investigator-initiated studies of mechanisms linking bariatric surgery to cancer risk.
Key Information: Clinical trials and unpublished preliminary data are not allowed; feasibility must not already be established.
The National Cancer Institute (NCI) offers this R21 exploratory/developmental grant to support proof-of-concept studies investigating how bariatric surgery affects cancer risk. The program seeks to engage bariatric surgery researchers in cancer research rather than shorter-term outcomes such as weight loss and diabetes. Studies may involve animal models, humans, or both, and should focus on sleeve gastrectomy and Roux-en-Y gastric bypass, the procedures currently in common use.
Relevant questions include surgery-specific versus weight-loss effects, differences by sex or surgical procedure, colorectal cancer risk, genetic predisposition, and microbiome-mediated mechanisms. The emphasis is on biological mechanisms linked to actual cancer endpoints, not solely intermediate biomarkers or epidemiologic associations. Applications involving collaborators outside cancer research receive special programmatic consideration.